{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009820","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.103502+00:00","generated_at":"2026-05-16T10:54:50.074196+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Erasca reports early PRs for ERAS-0015 at 8 mg QD; Phase 1 dose escalation faster than expected","bullets":["ERAS-0015 AURORAS-1 trial: two confirmed PRs and one unconfirmed PR in patients with different tumor types and RAS mutations at 8 mg QD.","No dose-limiting toxicities; predominantly low-grade AEs; linear PK across all dose levels evaluated (data cutoff Jan 7, 2026).","Initial Phase 1 monotherapy data for ERAS-0015 planned for H1 2026; expansion/combination cohorts start H2 2026.","ERAS-4001 BOREALIS-1 Phase 1 dose escalation advancing as expected; initial monotherapy data planned H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009820","json":"https://secwatch.observer/filing/0001193125-26-009820.json","markdown":"https://secwatch.observer/filing/0001193125-26-009820.md","text":"https://secwatch.observer/filing/0001193125-26-009820.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526009820/0001193125-26-009820-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526009820/eras-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:54:50.074196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}